Congress Asset Management Co. MA Sells 586 Shares of Eli Lilly and Company (NYSE:LLY)

Congress Asset Management Co. MA decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 0.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 225,917 shares of the company’s stock after selling 586 shares during the period. Eli Lilly and Company accounts for approximately 1.3% of Congress Asset Management Co. MA’s portfolio, making the stock its 8th biggest holding. Congress Asset Management Co. MA’s holdings in Eli Lilly and Company were worth $175,754,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Eli Lilly and Company by 0.9% in the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after buying an additional 659,838 shares in the last quarter. Capital World Investors boosted its stake in shares of Eli Lilly and Company by 0.3% in the fourth quarter. Capital World Investors now owns 26,949,773 shares of the company’s stock valued at $15,709,466,000 after buying an additional 89,720 shares in the last quarter. Morgan Stanley boosted its stake in shares of Eli Lilly and Company by 0.7% in the third quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock valued at $6,738,605,000 after buying an additional 83,915 shares in the last quarter. Norges Bank purchased a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $5,992,890,000. Finally, Capital Research Global Investors boosted its stake in shares of Eli Lilly and Company by 4.5% in the fourth quarter. Capital Research Global Investors now owns 7,577,592 shares of the company’s stock valued at $4,417,120,000 after buying an additional 325,342 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 194,978 shares of the firm’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $885.91, for a total transaction of $172,732,959.98. Following the completion of the sale, the insider now directly owns 97,583,810 shares of the company’s stock, valued at approximately $86,450,473,117.10. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, major shareholder Lilly Endowment Inc sold 194,978 shares of the firm’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $885.91, for a total transaction of $172,732,959.98. Following the completion of the sale, the insider now directly owns 97,583,810 shares of the company’s stock, valued at approximately $86,450,473,117.10. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the sale, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The disclosure for this sale can be found here. Insiders sold a total of 762,804 shares of company stock valued at $648,109,138 in the last three months. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $883.88 on Friday. The stock has a fifty day moving average price of $798.59 and a two-hundred day moving average price of $728.91. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The firm has a market cap of $840.05 billion, a P/E ratio of 130.17, a PEG ratio of 1.93 and a beta of 0.36. Eli Lilly and Company has a 1 year low of $434.34 and a 1 year high of $905.45.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm’s quarterly revenue was up 26.0% on a year-over-year basis. During the same period last year, the company posted $1.62 EPS. Research analysts forecast that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 10th. Stockholders of record on Thursday, May 16th were paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 0.59%. The ex-dividend date was Wednesday, May 15th. Eli Lilly and Company’s dividend payout ratio is presently 76.58%.

Wall Street Analyst Weigh In

LLY has been the topic of a number of research analyst reports. Citigroup boosted their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. BMO Capital Markets boosted their target price on Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 1st. Truist Financial boosted their target price on Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Finally, Jefferies Financial Group boosted their price target on Eli Lilly and Company from $925.00 to $957.00 and gave the stock a “buy” rating in a report on Friday, June 7th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $803.50.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.